Kayexalate and Calcium carbonate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Kayexalate (sodium polystyrene sulfonate) and Calcium carbonate (calcium). Common drug interactions include hyperparathyroidism among females and malignant pleural effusion among males.

The phase IV clinical study analyzes what interactions people have when they take Kayexalate and Calcium carbonate. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Kayexalate?

Kayexalate has active ingredients of sodium polystyrene sulfonate. eHealthMe is studying from 5,004 Kayexalate users. Check the latest studies of Kayexalate.

What is Calcium carbonate?

Calcium carbonate has active ingredients of calcium. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 16,045 Calcium carbonate users. Check the latest studies of Calcium carbonate.

On Jul, 16, 2026

25 people who take Kayexalate and Calcium carbonate together, and have interactions are studied.

Kayexalate and Calcium carbonate drug interactions.

What are the common drug interactions of Kayexalate and Calcium Carbonate, by gender? *:

female:

Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium)
Hypoaesthesia oral (reduced sense of touch or sensation in mouth)
Hypokalaemia (low potassium)
Hypotension (abnormally low blood pressure)
Immunosuppression
Impaired gastric emptying
Infection
Inflammation
Influenza like illness
Intra-abdominal pressure increased

male:

Malignant pleural effusion (a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue lining of lung)
Plasmacytoma (neoplasm of plasma cells (usually in bone marrow))
Feeling hot
Gait disturbance
Hypertension (high blood pressure)
Lung disorder (lung disease)
Pain in extremity
Pleural effusion (water on the lungs)
Poor peripheral circulation
Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin)

What are the common drug interactions of Kayexalate and Calcium Carbonate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Hypertension (high blood pressure)

10-19:

n/a

20-29:

n/a

30-39:

Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
Rash erythematous (redness of the skin)

40-49:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)

50-59:

Hypercholesterolaemia (high levels of cholesterol in the blood)
Hyperhidrosis (abnormally increased sweating)
Hyperlipidaemia (presence of excess lipids in the blood)
Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium)
Hypoaesthesia oral (reduced sense of touch or sensation in mouth)
Hypokalaemia (low potassium)
Hypotension (abnormally low blood pressure)
Impaired gastric emptying
Infection
Inflammation

60+:

Malignant pleural effusion (a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue lining of lung)
Plasmacytoma (neoplasm of plasma cells (usually in bone marrow))
Clostridium colitis (inflammation of colon by clostridium difficile bacteria infection)
Death
Feeling hot
Gait disturbance
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
General physical health deterioration (weak health status)
Hyperkalaemia (damage to or disease of the kidney)
Immunosuppression

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 4 people, 16.00%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 3 people, 12.00%
Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 3 people, 12.00%
High Blood Pressure: 3 people, 12.00%
Adverse Event: 3 people, 12.00%
Urinary Tract Infection: 2 people, 8.00%
Urinary Retention Postoperative: 2 people, 8.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 8.00%
Headache (pain in head): 2 people, 8.00%
Enlarged Prostate: 2 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Kayexalate and Calcium carbonate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously